Keep In Touch: Communication Maintains Ongoing Purdue/Shionogi Pact
The private US pain specialist and Japanese pharma have partnered for more than a decade to develop novel pain candidates, but despite perhaps slow progress, the level of collaboration has grown with strong communication.
You may also be interested in...
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.